CALIFORNIA NANOTECHNOLOGIES (CNO.CA) Fundamental Analysis & Valuation

TSX-V:CNO • CA1304921010

Current stock price

0.29 CAD
-0.01 (-1.69%)
Last:

This CNO.CA fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. CNO.CA Profitability Analysis

1.1 Basic Checks

  • In the past year CNO has reported negative net income.
  • CNO had a negative operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: CNO reported negative net income in multiple years.
  • Each year in the past 5 years CNO had a positive operating cash flow.
CNO.CA Yearly Net Income VS EBIT VS OCF VS FCFCNO.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1M 2M

1.2 Ratios

  • CNO's Return On Assets of -52.11% is on the low side compared to the rest of the industry. CNO is outperformed by 72.73% of its industry peers.
  • CNO has a Return On Equity of -100.49%. This is in the lower half of the industry: CNO underperforms 77.27% of its industry peers.
Industry RankSector Rank
ROA -52.11%
ROE -100.49%
ROIC N/A
ROA(3y)7%
ROA(5y)3.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CNO.CA Yearly ROA, ROE, ROICCNO.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100 -100 200

1.3 Margins

  • CNO's Operating Margin has improved in the last couple of years.
  • With an excellent Gross Margin value of 57.64%, CNO belongs to the best of the industry, outperforming 95.45% of the companies in the same industry.
  • CNO's Gross Margin has improved in the last couple of years.
  • CNO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 57.64%
OM growth 3Y4.57%
OM growth 5Y69.99%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.75%
GM growth 5Y3.23%
CNO.CA Yearly Profit, Operating, Gross MarginsCNO.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. CNO.CA Health Analysis

2.1 Basic Checks

  • CNO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • CNO has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for CNO has been increased compared to 5 years ago.
  • Compared to 1 year ago, CNO has a worse debt to assets ratio.
CNO.CA Yearly Shares OutstandingCNO.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M
CNO.CA Yearly Total Debt VS Total AssetsCNO.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 1M 2M 3M 4M 5M

2.2 Solvency

  • Based on the Altman-Z score of 0.42, we must say that CNO is in the distress zone and has some risk of bankruptcy.
  • CNO has a Altman-Z score of 0.42. This is in the lower half of the industry: CNO underperforms 63.64% of its industry peers.
  • A Debt/Equity ratio of 0.50 indicates that CNO is somewhat dependend on debt financing.
  • CNO's Debt to Equity ratio of 0.50 is in line compared to the rest of the industry. CNO outperforms 54.55% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.5
Debt/FCF N/A
Altman-Z 0.42
ROIC/WACCN/A
WACC9.34%
CNO.CA Yearly LT Debt VS Equity VS FCFCNO.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1M -1M 2M

2.3 Liquidity

  • A Current Ratio of 1.01 indicates that CNO should not have too much problems paying its short term obligations.
  • CNO has a worse Current ratio (1.01) than 72.73% of its industry peers.
  • CNO has a Quick Ratio of 1.01. This is a normal value and indicates that CNO is financially healthy and should not expect problems in meeting its short term obligations.
  • CNO has a Quick ratio (1.01) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.01
Quick Ratio 1.01
CNO.CA Yearly Current Assets VS Current LiabilitesCNO.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500K 1M 1.5M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. CNO.CA Growth Analysis

3.1 Past

  • CNO shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -551.43%.
  • Looking at the last year, CNO shows a very negative growth in Revenue. The Revenue has decreased by -49.89% in the last year.
  • CNO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 49.59% yearly.
EPS 1Y (TTM)-551.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1145.45%
Revenue 1Y (TTM)-49.89%
Revenue growth 3Y79.21%
Revenue growth 5Y49.59%
Sales Q2Q%-78.27%

3.2 Future

  • The Earnings Per Share is expected to decrease by -62.95% on average over the next years. This is quite bad
  • The Revenue is expected to decrease by -22.68% on average over the next years. This is quite bad
EPS Next Y100%
EPS Next 2Y104.05%
EPS Next 3Y-62.95%
EPS Next 5YN/A
Revenue Next Year-40.39%
Revenue Next 2Y-9.72%
Revenue Next 3Y-22.68%
Revenue Next 5YN/A

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
CNO.CA Yearly Revenue VS EstimatesCNO.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2M 4M 6M
CNO.CA Yearly EPS VS EstimatesCNO.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2027 2028 0 0.01 -0.01 -0.02

More info and screens

Find the best growth stocksShow best growing peers

2

4. CNO.CA Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for CNO. In the last year negative earnings were reported.
  • With a Price/Forward Earnings ratio of 20.70, CNO is valued on the expensive side.
  • Based on the Price/Forward Earnings ratio, CNO is valued a bit cheaper than the industry average as 68.18% of the companies are valued more expensively.
  • The average S&P500 Price/Forward Earnings ratio is at 23.84. CNO is around the same levels.
Industry RankSector Rank
PE N/A
Fwd PE 20.7
CNO.CA Price Earnings VS Forward Price EarningsCNO.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CNO.CA Per share dataCNO.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 -0.05

4.3 Compensation for Growth

  • The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • CNO's earnings are expected to decrease with -62.95% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y104.05%
EPS Next 3Y-62.95%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. CNO.CA Dividend Analysis

5.1 Amount

  • CNO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

CNO.CA Fundamentals: All Metrics, Ratios and Statistics

CALIFORNIA NANOTECHNOLOGIES

TSX-V:CNO (3/13/2026, 7:00:00 PM)

0.29

-0.01 (-1.69%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCapital Goods
GICS IndustryMachinery
Earnings (Last)N/A
Earnings (Next)N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners13.73%
Ins Owner ChangeN/A
Market Cap14.53M
Revenue(TTM)3.04M
Net Income(TTM)-2.15M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 20.7
P/S 3.52
P/FCF N/A
P/OCF N/A
P/B 5
P/tB 5
EV/EBITDA N/A
EPS(TTM)-0.06
EYN/A
EPS(NY)0.01
Fwd EY4.83%
FCF(TTM)0
FCFYN/A
OCF(TTM)0
OCFYN/A
SpS0.08
BVpS0.06
TBVpS0.06
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -52.11%
ROE -100.49%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 57.64%
FCFM N/A
ROA(3y)7%
ROA(5y)3.17%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)19.86%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y4.57%
OM growth 5Y69.99%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y1.75%
GM growth 5Y3.23%
F-Score3
Asset Turnover0.74
Health
Industry RankSector Rank
Debt/Equity 0.5
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 16.75%
Cap/Sales 3.94%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.01
Quick Ratio 1.01
Altman-Z 0.42
F-Score3
WACC9.34%
ROIC/WACCN/A
Cap/Depr(3y)145.85%
Cap/Depr(5y)N/A
Cap/Sales(3y)13.6%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-551.43%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-1145.45%
EPS Next Y100%
EPS Next 2Y104.05%
EPS Next 3Y-62.95%
EPS Next 5YN/A
Revenue 1Y (TTM)-49.89%
Revenue growth 3Y79.21%
Revenue growth 5Y49.59%
Sales Q2Q%-78.27%
Revenue Next Year-40.39%
Revenue Next 2Y-9.72%
Revenue Next 3Y-22.68%
Revenue Next 5YN/A
EBIT growth 1Y-212.12%
EBIT growth 3Y87.4%
EBIT growth 5Y154.28%
EBIT Next Year-67.13%
EBIT Next 3Y-32.55%
EBIT Next 5YN/A
FCF growth 1Y-140.98%
FCF growth 3Y80.29%
FCF growth 5Y42.36%
OCF growth 1Y-102.44%
OCF growth 3Y173%
OCF growth 5Y84.63%

CALIFORNIA NANOTECHNOLOGIES / CNO.CA Fundamental Analysis FAQ

What is the ChartMill fundamental rating of CALIFORNIA NANOTECHNOLOGIES (CNO.CA) stock?

ChartMill assigns a fundamental rating of 2 / 10 to CNO.CA.


What is the valuation status of CALIFORNIA NANOTECHNOLOGIES (CNO.CA) stock?

ChartMill assigns a valuation rating of 2 / 10 to CALIFORNIA NANOTECHNOLOGIES (CNO.CA). This can be considered as Overvalued.


How profitable is CALIFORNIA NANOTECHNOLOGIES (CNO.CA) stock?

CALIFORNIA NANOTECHNOLOGIES (CNO.CA) has a profitability rating of 3 / 10.